Data from the Phase III EMERGE trial show treatment with Symbravo provided more rapid and sustained migraine relief with ...

For patients with rheumatoid arthritis and inadequate response to JAK inhibitors, cycling to another JAK inhibitor is a more effective option than switching to a biological disease-modifying ...

Axsome Therapeutics (AXSM) announced that the EMERGE Phase 3 trial of SYMBRAVO in patients experiencing inadequate response to oral CGRP ...

Conclusion: Here we showed a six-gene ADCP signature that correlated with prognosis and immune modulation in ccRCC. The signature-based risk stratification was associated with response to both ICI and ...

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

1Georgetown University Medical Center, Washington, DC.

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Our findings demonstrate that HY-oAd and 9-ING-41 combination therapy (HY-oAd+9-ING-41) exerted superior inhibition of tumor growth compared with respective monotherapy in a syngeneic NMIBC tumor ...

The prognostic role of circulating tumor DNA (ctDNA) clearance as a biomarker in localized and metastatic renal cell carcinoma (RCC): A single-center experience. This is an ASCO Meeting Abstract from ...

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...